Glenmark gets first generic approvals for Advair MDI
This article was originally published in Scrip
While a recent FDA draft guidance raised hopes that cut-price versions of GlaxoSmithKline's blockbuster asthma/COPD product Advair (fluticasone/salmeterol) may arrive earlier than anticipated in the US, the Indian company, Glenmark, has received what's perhaps the first approval for a generic Advair MDI (metered-dose inhaler) in Mexico and the Philippines.
You may also be interested in...
Glenmark Pharmaceuticals Ltd., which is building its global respiratory play, appears to be betting big on its new next-generation digital inhaler that the India firm underscores is meaningful innovation that patients can afford. The jury, though, appears to be still out on whether India’s first digital dose inhaler (DDI) can help move the adherence needle.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.